A Review of Vinorelbine in the Treatment of Advanced Breast Cancer

Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumor types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC), and it is used in other cancer type such as prostate cancer, lymphomas, gynecologic malignancies. This agent has a generally favorable safety profile, and may be suitable for use in special populations such as the elderly and/or frail patient. However, with the taxanes established as standard second line treatment for ABC after failure of an anthracycline, Vinorelbine has been generally relegated for use as third line therapy, in competition with the oral compound Capecitabine. Combination regimens of Vinorelbine and Gemcitabine have been indeed widely studied, and have been demonstrated to be safe and effective. More recently, the exciting results observed with the combination of Vinorelbine and Trastuzumab in patients with Her-2 overexpressing tumors, as well as the development of a reliable formulation and revised schedule of oral Vinorelbine appear to have revived the interest in this compound in the management of this disease. Yet, data from properly designed randomized clinical trials are eagerly awaited to confirm the amount of available data which are mostly based on phase II studies.

• Publication year

  2009

• Venue

  Clinical Medicine and Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.4137/CMT.S1153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: A phase II trial.

  2016cited by this paper
• French experience of patient management when receiving oral vinorelbine chemotherapy (NVBO) for metastatic breast cancer: Final results of a prospective observational survey on practices.

  2016cited by this paper
• Capecitabine is associated with lower chemotherapy-related expenditures than those associated with gemcitabine in women with metastatic breast cancer.

  2009cited by this paper
• The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.

  2009cited by this paper
• Therapiebeurteilung aus Patientensicht – PROs (Patient Reported Outcomes)

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer

  2009cited by this paper
• Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

  2009cited by this paper
• All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

  2009cited by this paper
• Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

  2009cited by this paper
• Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.

  2008cited by this paper
• Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65 years of age

  2008cited by this paper
• Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group

  2008cited by this paper
• A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer.

  2008cited by this paper
• Capecitabine and Vinorelbine as First-Line Treatment in Elderly Patients (≥65 Years) with Metastatic Breast Cancer

  2008cited by this paper
• Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial

  2008cited by this paper
• Vinorelbine plus capecitabine in salvage therapy of breast cancer. Comparison of intravenous vs oral administration of vinorelbine

  2008cited by this paper
• Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer – a phase II trial

  2008cited by this paper
• Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >75 years old with metastatic breast cancer

  2008cited by this paper
• First step of oral vinorelbine and capecitabine combination in advanced breast cancer patients: Feasability study

  2008cited by this paper
• Vinorelbine and capecitabine combination as first-line treatment in patients with metastatic breast cancer: Final results of a multicentric trial in Egypt

  2008cited by this paper
• Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group

  2008cited by this paper
• A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

  2008cited by this paper
• Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (≥ 70 years)

  2008cited by this paper
• Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer

  2007cited by this paper
• Advanced breast cancer: chemotherapy phase III trials that change a standard

  2007cited by this paper
• Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer

  2007cited by this paper
• Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

  2007cited by this paper
• Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

  2007cited by this paper
• Survival Differences Observed in Metastatic Breast Cancer Patients Treated With Capecitabine When Compared With Vinorelbine After Pretreatment With Anthracycline and Taxane

  2007cited by this paper
• Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study.

  2006cited by this paper
• Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study.

  2006cited by this paper
• Metastatic breast cancer: an updating.

  2006cited by this paper
• Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

  2006cited by this paper
• High efficacy and low toxicity of the combination of vinorelbine and capecitabine as second line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.

  2006cited by this paper
• Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.

  2006cited by this paper
• A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

  2006cited by this paper
• Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

  2005cited by this paper
• Mitoxantrone plus vinorelbine in pretreated patients with advanced breast cancer

  2005cited by this paper
• A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC)

  2005cited by this paper
• Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.

  2005cited by this paper
• The absolute bioavailability of oral vinorelbine in patients with solid tumors

  2005cited by this paper
• Gemcitabine plus vinorelbine as first-line treatment of metastatic breast cancer

  2005cited by this paper
• Epirubicine-vinorelbine (EV) intravenous combination followed by oral vinorelbine (VNR) as first-line treatment in advanced breast cancer (ABC) patients: A POLONORD Group study

  2005cited by this paper
• Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer.

  2005cited by this paper
• Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.

  2004cited by this paper
• Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

  2004cited by this paper
• Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane

  2004cited by this paper
• Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

  2004cited by this paper
• Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cance.

  2004cited by this paper
• A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer

  2004cited by this paper
• Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.

  2004cited by this paper
• Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function.

  2004cited by this paper
• Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

  2004cited by this paper
• Pharmacokinetics of vinorelbine in man

  2004cited by this paper
• Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer.

  2004cited by this paper
• Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer

  2004cited by this paper
• Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.

  2004cited by this paper
• Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study.

  2004cited by this paper
• Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

  2003cited by this paper
• Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy

  2003cited by this paper
• Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer.

  2003cited by this paper
• Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study

  2003cited by this paper
• Is Gemcitabine plus Vinorelbine Active in Second-Line Chemotherapy of Metastatic Breast Cancer? A Single-Center Phase 2 Study

  2003cited by this paper
• Full Dose Paclitaxel Plus Vinorelbine as Salvage Chemotherapy in Anthracycline-Resistant Advanced Breast Cancer: A Phase II Study

  2003cited by this paper
• Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial.

  2003cited by this paper
• Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer

  2003cited by this paper
• The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase I–II Study

  2003cited by this paper
• Biweekly Docetaxel and Vinorelbine in Anthracycline‐Resistant Metastatic Breast Cancer: A Multicenter Phase II Study

  2003cited by this paper
• Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

  2003cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

  2002cited by this paper
• First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.

  2002cited by this paper
• Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

  2002cited by this paper
• Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer.

  2002cited by this paper
• A phase II study of intravenous navelbine and doxorubicin combination in previously untreated advanced breast carcinoma.

  2002cited by this paper
• A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer.

  2002cited by this paper
• Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer.

  2002cited by this paper
• Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

  2002cited by this paper
• Gemcitabine and Vinorelbine Combination in Patients with Metastatic Breast Cancer

  2002cited by this paper
• Docetaxel Plus Vinorelbine as Salvage Chemotherapy in Advanced Breast Cancer: A Phase II Study

  2002cited by this paper
• Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.

  2001cited by this paper
• Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.

  2001cited by this paper
• First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study.

  2001cited by this paper
• Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

  2001cited by this paper
• Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.

  2001cited by this paper
• Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.

  2001cited by this paper
• Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

  2001cited by this paper
• Oral vinorelbine: feasibility and safety profile.

  2001cited by this paper
• Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC)

  2001cited by this paper
• Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.

  2001cited by this paper
• Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.

  2001cited by this paper
• Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

  2001cited by this paper
• The prognostic value of contralateral, metachronous, and bilateral, synchronous breast cancer in breast cancer patients

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.

  2000cited by this paper
• Vinorelbine combined with paclitaxel infused over 96 hours (VI‐TA‐96) for patients with metastatic breast carcinoma

  2000cited by this paper
• Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel

  2000cited by this paper
• Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.

  2000cited by this paper
• First-Line Chemotherapy with Vinorelbine and Paclitaxel as Simultaneous Infusion in Advanced Breast Cancer

  2000cited by this paper

• Survival Analysis in Metastasis Breast Cancer with HER-2 Type That Received Vinorelbine And Capecitabine Chemotherapy at Prof. Dr.I.G.N.G. Ngoerah Central General Hospital

  2024cites this paper
• Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer

  2019cites this paper
• Natural Anticancer Compounds and Their Derivatives in Clinical Trials

  2017cites this paper